AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03289286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dedicated and coordinated e-follow-up.
Description: In pre- and post-surgery:~* Completion of questionnaires using an electronic tool,~* Telephone follow-up if necessary between the nurse and the patient.
Study NCT00007852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.
Study NCT00007852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: BCNU 300 mg/M2 IV day -6
Study NCT00007852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 100 mg/m2 on days -5 through -2
Study NCT00007852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100mg/M2 BID on days -5 through -2
Study NCT00007852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 IV on day -1
Study NCT00007852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
Study NCT04239833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028 tablets
Description: The initial dose of SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT04239833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo SH-1028 tablets
Description: The initial dose of Placebo SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT04239833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets).
Study NCT04239833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib
Description: The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.
Study NCT03314688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary/Physical Activity intervention
Description: Motivational counseling to follow established dietary and exercise guidelines.
Study NCT03314688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
Study NCT01305122 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neurocognitive tests
Description: * inclusion~* 1 year~* 3 years~* 5 years
Study NCT02109250 — intervention group
Intervention type: DRUG
Intervention: Caprelsa
Description: Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
Study NCT03328676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Study NCT03328676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Study NCT00725803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules administered orally once daily
Study NCT00511420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa product type 4
Description: 6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
Study NCT02237690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin hydrochloride liposome
Description: 50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
Study NCT02237690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride liposome
Description: 50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
Study NCT01472484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 586/8x87 white
Description: 2 x 50 g
Study NCT01472484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 586/8x87 brown
Description: 2 x 50 g
Study NCT01472484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAT 881
Description: 2 x 50 g
Study NCT01472484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 586/8
Description: 2 x 50 g
Study NCT03341884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: A single oral dose of 100 mg ipatasertib will be administered.
Study NCT02840136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Study NCT02840136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Study NCT02840136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Study NCT01412229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
Study NCT01412229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
Study NCT01412229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
Study NCT01554657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 Days of Antibiotics
Description: The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
Study NCT01554657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 7 Days of Antibiotics therapy for pneumonia
Description: The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
Study NCT01672957 — intervention group
Intervention type: DRUG
Intervention: Mycophenolate Mofetil
Description: Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
Study NCT01672957 — intervention group
Intervention type: DRUG
Intervention: Immunosuppressive Therapy
Description: Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
Study NCT00725803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450 Placebo
Description: Placebo to match GS-9450 administered orally once daily
Study NCT02453386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tozadenant
Study NCT02453386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02285894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory hold
Description: Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
Study NCT02371343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil, Ocean plus
Description: Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
Study NCT02371343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Study NCT03703791 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR101
Description: AR101 powder
Study NCT01523470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP Synchrony
Description: BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
Study NCT01523470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP Synchrony
Description: BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
Study NCT01924429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Escalating stepped dose titration: 30, 50 or 70mg
Study NCT04109339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
Study NCT00954252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 1x, oral capsule, single dose
Study NCT00954252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral capsule, single dose
Study NCT00954252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 2x, oral capsule, single dose
Study NCT00954252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 4x, oral capsule, single dose
Study NCT00954252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 8x, oral capsule, single dose
Study NCT00954252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 16x, oral capsule, single dose
Study NCT00954252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 24x, oral capsule, single dose
Study NCT01779271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelubiprofen
Study NCT01779271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen
Study NCT00184171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide 9 mg
Study NCT00184171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth mixture
Study NCT00184171 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fiber
Description: Fiber for control
Study NCT01821573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: Experimental arm group:~* 150 Units in rectus femoris ( 3 ml and 3 points)~* 70 units in medial gastrocnemius (1.4 ml and 1 point)~* 70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~* 60 units in soleus ( 1.2 ml and 3 points)
Study NCT01821573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of NaCl 0.9%
Description: Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points
Study NCT01465685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 125 mg per os, single dose
Study NCT01465685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
Study NCT01465685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules identical to MDMA or methylphenidate
Study NCT01226121 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clostridial collagenase injectable
Description: Finger manipulation performed 1, 2, or 4 days following collagenase injection
Study NCT04592484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDK-002
Description: CDK-002 administered intratumorally
Study NCT00535574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bexarotene (Targretin LGD1069)
Description: 75 mg per day for 6 weeks
Study NCT00535574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexarotene (Targretin LGD1069)
Description: 75 mg per day for 6 weeks
Study NCT00535574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bexarotene
Description: 75 mg/day 6 weeks
Study NCT03627390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Study NCT03627390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C2
Description: BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
Study NCT03314246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FAST
Description: Fasting Algorithm for Singaporeans with Type 2 Diabetes
Study NCT03314246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care
Study NCT02339220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Description: Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
Study NCT02339220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lakeshore Enriched Fitness Training (LEFT)
Description: This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
Study NCT02339220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard Transfer Package (sTP)
Description: This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
Study NCT02339220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard Transfer Package (sTP)
Description: This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
Study NCT02339220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced Transfer Package (eTP)
Description: This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
Study NCT02339220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: enhanced Transfer Package (eTP)
Description: This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
Study NCT02203175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Before the anesthesia induction, 5 ml isotonic saline
Study NCT02203175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl
Description: before the anesthesia induction 50 mcgr fentanyl
Study NCT02203175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: before the anesthesia induction 50 mcgr fentanyl
Study NCT02203175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: during anesthesia 50 mg proposal with 50 mcgr fentanyl
Study NCT02203175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: during anesthesia 50 mg proposal with 50 mcgr fentanyl
Study NCT00773045 — intervention group
Intervention type: OTHER
Intervention: A Pain training program and pain measurement
Description: Comparing patients treated with and without analgesia and sedation protocol
Study NCT01253707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 337
Description: AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
Study NCT01051089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Exercise and diet education
Study NCT04371796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab injection
Description: Sintilimab injection 200mg, 2cycles of treatment before surgery
Study NCT01557790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Study NCT01439815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Nasal Spray
Description: two sprays in each nostril once daily
Study NCT01439815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: two sprays in each nostril once daily